Key Highlights
- Genialis partners with PanCAN to validate the krasID biomarker for pancreatic cancer.
- krasID predicts response to KRAS inhibitors in clinical and real-world settings.
- Presented at ASCO 2024, demonstrating significant predictive accuracy.
Source: Business Wire
Notable Quotes
- “Pancreatic cancer is a tough disease with few treatment options, and currently the 5-year survival rate is 13 percent. By partnering with Genialis, we will lever the data from PanCAN’s Know Your Tumor precision medicine service to further validate Genialis krasID biomarker performance in pancreatic cancer,” — Anna Berkenblit, M.D., MMSc, Chief Scientific and Medical Officer at PanCAN
- “The RAS gene family is the original white whale of cancer drug targets. Since the discovery of RAS genes and their role in promoting cancer over 40 years ago, patients, physicians, and cancer researchers have been on the hunt for a safe and effective drug against this behemoth. Yet, there are still limited treatment options,” — Rafael Rosengarten, Ph.D., CEO at Genialis
SoHC's Take
The partnership between Genialis and PanCAN represents a significant stride in the battle against pancreatic cancer. By leveraging advanced AI classifiers like Genialis krasID, which predict responses to KRAS inhibitors, this collaboration aims to bring more personalized and effective treatment options to patients. The validation of krasID as a reliable biomarker could revolutionize how pancreatic cancer is treated, offering hope for improved outcomes in a disease known for its dire prognosis. The impressive predictive accuracy of krasID, as demonstrated in various studies, underscores its potential as a game-changer in oncological diagnostics and personalized medicine.
